In a report released today, Nico Chen from DBS maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of $100.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Nico Chen has given his Buy rating due to a combination of factors influencing Gilead Sciences’ stock outlook. A key driver is the anticipated approval of Seladelpar, a promising treatment for primary biliary cholangitis, which could significantly enhance the company’s share price. The completion of phase 3 trials with positive outcomes positions Gilead as a leader in addressing unmet medical needs, particularly for the 40% of patients who cannot tolerate the current standard treatment.
Additionally, Gilead’s robust HIV and cancer drug portfolio continues to bolster sales and maintain high profit margins. The substantial year-over-year growth in their cell therapy products, particularly Trodelvy, underscores their competitive edge in the market. Coupled with consistent dividend increases, reflecting strong cash reserves and confidence in future cash flows, these elements collectively justify a target price of USD 100.00 per share, suggesting a Buy recommendation.
Chen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Gilead Sciences, and Sanofi. According to TipRanks, Chen has an average return of 5.7% and a 57.58% success rate on recommended stocks.
In another report released on February 13, DZ BANK AG also upgraded the stock to a Buy with a $108.00 price target.